- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01913301
A Randomized Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Effects of Alagebrium on Exercise in Subjects With Diastolic Heart Failure (BREAK-DHF-1)
July 30, 2013 updated by: Cardiovascular Clinical Studies
The purpose of the study is to gather information regarding the safety and effectiveness of an investigational drug called Alagebrium when used treating Heart Failure in relation to exercise tolerance after 6 months in the trial.
Study Overview
Study Type
Interventional
Enrollment (Actual)
134
Phase
- Phase 2
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
50 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Males and females 50 years of age or older.
- Diagnosis of diabetes OR a diagnosis of hypertension requiring therapy.
- Echocardiographic ejection fraction ≥ 45% verified within 1 year prior to baseline, assuming no intercurrent cardiac event between the echo and screening.
- Echocardiographic evidence of diastolic dysfunction as defined by an E/E' ≥ 12 determined within 1 year prior to baseline; sinus rhythm required at time of echo.
- Previous hospitalization due to heart failure OR a current or previous BNP ≥ 100 pg/mL.
- New York Heart Association (NYHA) functional class II-IV.
- At least 1 month between hospitalization for heart failure and randomization.
- Stable doses of heart failure medications (diuretics, ACE inhibitors, ARB's, beta-adrenergic antagonists, aldosterone antagonists) for at least 1 month prior to randomization.
- Able to understand content of and willing to provide written informed consent.
- Agree to use adequate contraception during the study if premenopausal. -
Exclusion Criteria:
- Ejection fraction < 45%.
- Screening Six-minute walk test > 450 meters or < 100 meters
- Clinically significant cardiac valvular disease (mitral regurgitation (MR) > grade I, aortic insufficiency (AI) > grade 1, mitral stenosis (MS), aortic stenosis (AS)).
- History of stroke, any sequelae of a transient ischemic attack (TIA), or reversible ischemic neurological defect (RIND) within 6 months prior to screening.
- History of acute myocardial infarction within 6 months prior to screening.
- Severe COPD as defined by O2 or steroid dependence.
- History of systemic inflammatory or collagen vascular disease.
- Active and or treated malignancies within 12 months prior to Visit 1 with the exception of basal cell carcinoma.
- Any significant systemic illness(es) or medical condition(s) that could lead to difficulty complying with the protocol; or any concurrent condition(s) which, in the investigator's opinion, would prohibit the subject from completing the study, or would not be in the best interest of the subject.
- Estimated glomerular filtration rate (GFR) ≤ 30 mL/min/1.73m² as calculated by Modification of Diet in Renal Disease (MDRD) study equation [MDRD = 186 X serum creatinine (mg/dl) 1.154 X years -0.203 X (0.742 if female) X (1.210 if African American)].
- Liver function tests (SGOT and/or SGPT) > 2.5 times the upper limit of normal range.
- Hb < 10 g/dL.
- Use of any investigational drug(s) within 30 days prior to screening.
- Previous exposure to alagebrium.
- Known seropositivity for HIV or hepatitis C, or presence of hepatitis B surface antigen.
Pregnancy or active breast-feeding. Urine pregnancy tests will be performed on all women who are not post-menopausal for at least 1 year.
-
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Alagebrium
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Exercise Tolerance
Time Frame: Change from baseline at Week 24
|
To evaluate the safety and efficacy of alagebrium in subjects diagnosed with diastolic heart failure.
The primary variable for assessing efficacy will be assessment of exercise tolerance using the Six-minute walk test.
|
Change from baseline at Week 24
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2007
Primary Completion (Actual)
May 1, 2009
Study Completion (Actual)
May 1, 2009
Study Registration Dates
First Submitted
February 15, 2013
First Submitted That Met QC Criteria
July 30, 2013
First Posted (Estimate)
August 1, 2013
Study Record Updates
Last Update Posted (Estimate)
August 1, 2013
Last Update Submitted That Met QC Criteria
July 30, 2013
Last Verified
February 1, 2013
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ALT-711-0530
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diastolic Heart Failure
-
Emory UniversityUnknownDiastolic Heart Failure | Diastolic DysfunctionUnited States
-
CorAssist Cadiovascular Ltd.RecruitingDiastolic Heart Failure | Diastolic DysfunctionIsrael
-
University of VermontCompletedDiastolic Heart Failure | Diastolic Dysfunction | PacemakerUnited States
-
University of NebraskaTerminatedDiastolic Heart FailureUnited States
-
Arizona State UniversityMayo Clinic; University of AlbertaCompleted
-
University of Wisconsin, MadisonTerminatedDiastolic Heart FailureUnited States
-
University of PennsylvaniaCompletedHeart Failure | Diastolic Heart FailureUnited States
-
Chang Gung Memorial HospitalCompleted
-
Duke UniversityNational Heart, Lung, and Blood Institute (NHLBI); PfizerCompleted
-
St Vincent's University Hospital, IrelandCompletedThe Effect of Eplerenone and Atorvastatin on Markers of Collagen Turnover in Diastolic Heart FailureDiastolic Heart FailureIreland
Clinical Trials on Alagebrium
-
Synvista Therapeutics, IncNational Institutes of Health (NIH)CompletedSTRETCH Study: Effect of Distensibility on Endothelial-Dependent Vasoreactivity in Patients With ISHCardiovascular DiseaseUnited States
-
Synvista Therapeutics, IncCompleted
-
Synvista Therapeutics, IncTerminatedDiastolic Heart FailureUnited States
-
Synvista Therapeutics, IncTerminatedChronic Heart FailureUnited States
-
Synvista Therapeutics, IncNational Institutes of Health (NIH); National Heart and Lung InstituteCompletedCardiovascular DiseaseUnited States
-
Synvista Therapeutics, IncJuvenile Diabetes Research FoundationTerminatedDiabetes Mellitus, Type 1 | Diabetic NephropathyAustralia, Denmark
-
Synvista Therapeutics, IncTerminated
-
University of Texas Southwestern Medical CenterNational Institute on Aging (NIA)CompletedVentricular FunctionUnited States
-
Radboud University Medical CenterDutch Heart Foundation; Synvista Therapeutics, IncCompletedCardiovascular Disease | Physical Activity | Aging | Endothelial DysfunctionNetherlands